The human concentrative nucleoside transporter, CNT3 (SLC28A3), plays an important role in mediating the cellular entry of a broad array of physiological nucleosides and synthetic anticancer nucleoside analog drugs. As a first step toward understanding the genetic basis for interindividual differences in the disposition and response to antileukemic nucleoside analogs, we examined the genetic and functional diversity of CNT3. In all, 56 variable sites in the exons and flanking intronic region of SLC28A3 were identified in a collection of 270 DNA samples from US populations (80 African-Americans, 80 European-Americans, 60 Asian-Americans, and 50 Mexican-Americans). Of the 16 coding region variants, 12 had not been previously reported. Also, 10 resulted in amino-acid changes and three of these had total allele frequencies of Z1%. Nucleotide diversity (p) at nonsynonymous and synonymous sites was estimated to be 1.81 Â 10 4 and 18.13 Â 10 4 , respectively, suggesting that SLC28A3 is under negative selection. All nonsynonymous variants, constructed by site-directed mutagenesis and expressed in Xenopus laevis oocytes, transported purine and pyrimidine model substrates, except for c. 1099G4A (p. Gly367Arg). This rare variant alters an evolutionarily conserved site in the putative substrate recognition domain of CNT3. The presence of three additional evolutionarily conserved glycine residues in the vicinity of p. Gly367Arg that are also conserved in human paralogs suggest that these glycine residues are critical in the function of the concentrative nucleoside transporter family. The genetic analysis and functional characterization of CNT3 variants suggest that this transporter does not tolerate nonsynonymous changes and is important for human fitness.
INTRODUCTION
Nucleosides serve as intermediates for essential biosynthetic cellular pathways, are important regulators of neurotransmission and cardiovascular activity, and act as signaling molecules. 1 Many synthetic analogs of purine and pyrimidine nucleosides are currently used in cancer and viral chemotherapy. Naturally occurring nucleosides and most synthetic nucleoside analogs are hydrophilic and require nucleoside transporters to traverse biological membranes. Therefore, nucleoside transporters are critical determinants of cellular and whole-body homeostasis of naturally occurring nucleosides and are important players in the tissue-specific disposition and pharmacokinetics of nucleoside analog drugs.
CNT3 is one of three recently cloned members of the SLC28 concentrative nucleoside transporter family. 2 In contrast to CNT1 and CNT2, CNT3 is broadly selective, transporting both purine and pyrimidine nucleosides. Among the cloned human SLC28 transporters, CNT3 is primarily responsible for the transport of several antileukemic drugs, such as cladribine and fludarabine. 2, 3 CNT3 has a 2 : 1 Na þ /nucleoside coupling ratio, allowing it to concentrate nucleosides intracellularly 10 times more efficiently than CNT1 or CNT2, which have a 1 : 1 Na þ /nucleoside coupling ratio. 2 Its localization to the apical membrane of the intestine and liver epithelia suggests that CNT3 plays an important role in the absorption and disposition of nucleosides and synthetic nucleoside analogs. 3 A major clinical problem in cancer treatment is intrinsic resistance to the initial drug regimen selected. Although nucleoside analogs (eg, cladribine, fludarabine, and cytarabine) are highly active in lymphoproliferative disorders, a significant portion of patients is resistant to these agents. 4, 5 This heterogenous response to treatment could be explained, at least in part, by interindividual variability in the expression and/or activity of nucleoside transporters. For example, recent studies have shown that variation in the intracellular transport of fludarabine correlated with its chemosensitivity. 6 In addition, analysis of expression levels of nucleoside transporters in leukemic cells suggests that CNT3 has the highest interindividual variability. 6 Gray et al 7 recently reported that several genetic variants of CNT1 exhibited altered interaction with gemcitabine, suggesting that common CNT1 variants may contribute to variation in systemic and intracellular levels of pyrimidine nucleoside analog drugs. As CNT3 is an important determinant of the disposition of physiological nucleosides and nucleoside analogs, we proposed to undertake a comprehensive genetic and functional analysis of CNT3 in ethnically diverse populations. Our study had two major goals: (1) to identify and analyze genetic variation in SLC28A3, and (2) to functionally characterize the protein-altering variants of CNT3.
RESULTS

Analysis of Genetic Variation in SLC28A3
Genetic variants of SLC28A3 were identified as part of a large study, the Pharmacogenetics of Membrane Transporters project, which entails identifying variants in membrane transporter genes that may determine differences in drug response and disposition. The 18 coding exons of SLC28A3 and 50-200 bp of flanking intronic sequence were screened in a collection of 270 ethnically diverse genomic DNA samples. The data can be found at http://www.pharmgkb. org. In all, 56 variants were identified in a total of 5997 bp screened, with a frequency of approximately 10 singlenucleotide polymorphisms (SNPs) per kb of sequence (Table 1) . A total of 40 variable sites were found in the noncoding intronic regions of the gene. Of the 16 coding region variants (cSNPs), 10 altered the protein sequence and 12 were not previously reported in dbSNP (http://www. ncbi.nlm.nih.gov/SNP). Figure 1 shows the position of the 16 cSNPs in the proposed topology of CNT3. 2 The majority of nonsynonymous variants were found in intracellular or extracellular loops (seven out of 10).
Three nonsynonymous variants (c. 338A4G; c. 14G4A; c. 982A4G) had total allele frequencies of Z1% (Table 1) . c. 338A4G (p. Tyr113Cys) was found in all populations sampled; c. 14G4A (p. Ser5Asn) was present in both the African-American and European-American population samples; and c. 982A4G (p. Ile328Val) was only found in the African-American population sample. p. Tyr113Cys was the only protein-altering variant with a particularly high allele frequency in all the ethnic groups (10.4%). The other seven protein-altering variants were singletons, meaning that they were found on only one of 540 chromosomes. Table 2 provides a summary of the estimates for the neutral parameter (y), nucleotide diversity (p), and Tajima's D statistic. These were calculated for the entire population and for each ethnic group. For the entire sample, y ( Â 10 4 ) and p ( Â 10 4 ) were 12.6372.93 and 6.1173.43, respectively. These estimates are consistent with a previous analysis of 24 membrane transporter genes. 8 The p ( Â 10 4 ) for synonymous (p S ) and nonsynonymous (p NS ) sites were 18.137 14.19 and 1.8172.13, respectively, suggesting that selection is acting against amino-acid changes in CNT3. As most values of y were greater than p, values for Tajima's D statistic were mostly negative, which is consistent with either recent population expansion or negative selection. Nucleotide diversity in both loop and transmembrane domain (TMD) regions was low (p loopÀNS ¼ 0.62 vs p TMDÀNS ¼ 3.72), suggesting that there are evolutionary constraints on both regions of the protein.
Analysis of SLC28A3 Haplotypes
Haplotypes of SLC28A3 were inferred from 32 population variable sites using the Bayesian statistical method of PHASE. 9 A total of 52 haplotypes were identified, of which 35 occurred on at least two chromosomes ( Figure 2 ). As the combined frequency of the 35 haplotypes was 99%, we focused our analysis on this group. The haplotypes were named according to a modified convention of Nebert following two main criteria: evolutionary divergence and frequency in the sample. 10 Haplotype *1A1 was the most common haplotype accounting for about 40% of the total sample. Six haplotypes (*1A1, *2A1A1, *3A1, *4A1, *5A1, and *6A1) had a total frequency Z5%. Of the 35 haplotypes, 17 (49%) were found only in one ethnic group. In contrast, only four of the 35 haplotypes (11%), *1A1, *2A1B, *3A1, and *4A1, were present in all ethnic groups. As expected, the AfricanAmerican population had the greatest number of haplotypes (24 out of 35), as well as the greatest number of ethnic specific haplotypes (11 out of 17). The common nonsynonymous variant, p. Tyr113Cys, was present in a common haplotype (*3A1) that was found in all ethnic groups. Some samples contained amplicons that could not be sequenced. Allele frequencies were calculated from actual DNA samples sequenced. Total, entire sample; AA, African-American; EA, European-American; AS, Asian-American; ME, Mexican-American; n, number of chromosomes.
Genetic variation of CNT3
I Badagnani et al The subsequent rows show each of the 35 haplotypes clustered and named according to their evolutionary divergence and population frequencies using a modified convention of Nebert. 10 A black filled square indicates that there is no change from the reference allele; a green filled square indicates a synonymous change in the coding region; a red filled square indicates a nonsynonymous change; a yellow filled square indicates a change at a noncoding site. Letters in the squares indicate the base pair change and a '-' indicates a deletion. Haplotypes were predicted using PHASE software version 1.0.1 as described previously. 9 Right panel, frequencies of each haplotype in the total population and in each ethnic group. Total, entire sample; AA, African-American; EA, European-American; AS, Asian-American; ME, Mexican-American. Data are mean7SD.
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Functional Characterization of Nonsynonymous Variants in CNT3
The 10 protein-altering variants of CNT3 were obtained by site-directed mutagenesis of the CNT3-reference template and were screened for functional activity in Xenopus laevis oocytes. Since CNT3 has broad substrate selectivity, two model substrates were used for the initial functional screen: the naturally occurring purine nucleoside, inosine, and the pyrimidine nucleoside, thymidine. As shown in Figure 3a , with the exception of one of the 10 nonsynonymous variants (p. Gly367Arg), which showed an 80-85% reduction in the transport of both purine and pyrimidine model substrates (Po0.0001, unpaired Student's t-test with Bonferroni correction for multiple testing), all variants of CNT3 transported both inosine and thymidine. p. Gly367Arg changed an evolutionarily conserved site, which is also conserved in the two human paralogs, CNT1 and CNT2. This variant was found on a single chromosome in the Asian-American sample and results in a radical chemical change (Grantham value of 125). 11 In addition, this variant occurred in the middle of TMD 8, which is considered to be part of the substrate recognition domain for CNTs. 12 Functional transport of the p. Gly367Arg variant was restored to normal levels after the variant sequence was changed to the reference sequence demonstrating that this amino-acid change was responsible for the reduced activity ( Figure 3a, Gly367Arg reversed) .
We examined the functional consequences of the three common nonsynonymous variants (p. Ser5Asn, p. Tyr113Cys, and p. Ile328Val) using the antileukemic adenosine analogs, cladribine and fludarabine. We first determined that the transport profile of the three common variants for adenosine and its analogs was similar to CNT3 reference (Figure 3b) . Then, the uptake of 0.1 mM 3 H-inosine in the presence of increasing concentrations of unlabeled adenosine, cladribine, or fludarabine was measured in oocytes expressing the reference and variant constructs. For these kinetic studies, we selected time based on initial transport rates where substrate uptake is linear (5 min for adenosine and 20 min for cladribine and fludarabine). (Table 3; 19 ) for the entire sample and for each ethnic group. The ratio of p NS /p S was 0.1, which is lower than 0.23 reported in a recent analysis of variation in 24 membrane transporter genes. 8 These observations suggest that CNT3 is under strong negative selection, which is acting to preserve its amino-acid sequence more so than in the case of many membrane transporters. Strong negative selection is also suggested by the values of Tajima's D for nonsynonymous sites, which were consistently negative compared to the corresponding values for synonymous sites, which were always positive for each of the ethnic groups analyzed. In addition, the majority of nonsynonymous variants in CNT3 occurred at an allele frequency lower than synonymous variants, where seven out of 10 protein-altering changes compared to just one out of six synonymous changes were singletons. Furthermore, a greater proportion of nonsynonymous variants was population specific (eight out of 10) compared to synonymous variants (two out of six). This is consistent with the theory that deleterious mutations (which are more likely to be at nonsynonymous sites) are kept at low frequency and should not easily spread to multiple populations. 13 The fact that CNT3 has few nonsynonymous changes may be ascribed to important endogenous roles of this transporter in regulating cellular and whole organ homeostasis of physiological nucleosides. 14 A total of 52 haplotypes were identified in SLC28A3, which is consistent with a report by Stephens et al, where the 313 genes analyzed had between two and 53 haplotypes. 15 Most haplotypes had only synonymous or intronic changes, while only nine of 35 haplotypes contained one amino-acid-altering variant. None of the haplotypes contained two or more amino-acid changes.
Of the 10 nonsynonymous variants identified in CNT3, one showed severely reduced functional transport of both purine and pyrimidine model substrates (Figure 3a) . p. Gly367Arg changed an evolutionarily conserved residue, which is also conserved in human paralogs of CNT3, and was found on a single chromosome in the Asian-American sample. In addition, this variant results in a radical chemical change with a Grantham value of 125 and is found in the middle of TMD 8, which is part of the putative substrate recognition domain of CNTs. 11, 12 These observations are consistent with findings that rare variants are more likely to affect function than common variants and that changes at evolutionarily conserved sites are more likely to be deleterious to protein function. 8, 16 In addition, Shu et al analyzed protein-altering variants of the organic cation transporter, OCT1, and found that combining evolutionary conservation with Grantham values was a stronger predictor of function. 17 Interestingly, TMD 8 of CNT3 has four glycines, including Gly367, which are conserved not only among mammals, but also in the other two human paralogs (CNT1 and CNT2), suggesting that these residues may be particularly important for the function of the concentrative nucleoside transporter family. A similar observation was also recently reported by Shu et al 17 for the organic cation transporter family, where all three of the nonfunctional variants of OCT1 altered evolutionarily conserved glycine residues. Vitkup et al 18 estimated that mutations at glycine residues are responsible for about 20% of genetic diseases and changes at glycine residues have the third highest probability (behind changes at cysteine and tryptophan, respectively) of causing an altered phenotype. This may be related to the important structural roles played by this residue. 19 In particular, glycine is frequently found at the turns of alpha-helices and if mutated may result in backbone strain, which may negatively impact the structural stability of a protein. 20 Partridge et al 21 recently reported that the Gly-Arg change accounts for approximately 5% of all phenotypic mutations in TMDs of various membrane proteins and occurs statistically more frequently in TMDs than in soluble domains. This is not surprising, since glycine residues are involved in van der Waals mediated packing of transmembrane helices. 22 Introducing an arginine residue in place of a glycine would then have dual deleterious effects of disrupting helixhelix interactions and introducing nonnative electrostatic interactions.
Comparison of nucleoside transporters suggests that there is a continuum in the genetic diversity, haplotype structure, and functional variation of these transporters. ENT1 (in the SLC29 equilibrative nucleoside transporter family), which has the least genetic and functional variation and is most constrained, is at one end of the spectrum, while CNT1, which has the most genetic and functional variation and is least constrained, is at the opposite extreme, with CNT3 in between. 7, 23 It is interesting that CNT3 has less genetic and functional diversity than its paralog, CNT1, suggesting that it is more critical for human fitness. The fact that both purine and pyrimidine nucleosides are substrates of CNT3, while only pyrimidine nucleosides are substrates of CNT1, suggests that CNT3 is able to replace the function of CNT1 in tissues where these transporters are co-expressed, whereas the reverse is not true. Moreover, because of its more favorable Na þ /nucleoside stoichiometry, CNT3 is capable of concentrating its substrates 10-fold more than CNT1. Thus, CNT3 may be a more important transporter in terms of human fitness than CNT1 and, as a result, it tolerates less genetic and functional diversity. Nonsynonymous variants of CNT3, as well as of ENT1 and CNT1, have less functional diversity than those of the xenobiotic transporter, OCT1. 7, 17, 23 A possible explanation for this phenomenon could be that transporters with a primary role in xenobiotic detoxification may be functionally less constrained compared to transporters, like CNT3, which though involved in xenobiotic disposition, function primarily to maintain homeostasis of endogenous compounds.
CNT3 plays an important role in modulating the disposition and entry of nucleoside analog drugs into target tissues.
3 CNT3 has been shown to interact with a variety of purine and pyrimidine analogs, including the antileukemic agents, cladribine and fludarabine. 2 These agents are currently considered the first drugs of choice in the treatment of a variety of lymphoproliferative disorders, such as chronic lymphocytic leukemia. 4, 5 Recently, Molina-Arcas et al 6 showed that leukemic cancer cells had varying abilities to concentrate fludarabine intracellularly and this correlated with fludarabine cytotoxicity. These same cells had variable expression levels of nucleoside transporters, with CNT3 showing the highest interindividual variation. 6 Therefore, in this study we examined the potency of interaction of cladribine and fludarabine with CNT3 and the three common protein-altering variants, p. Ser5Asn, p. Tyr113Cys, and p. Ile328Val (Figure 4) . No significant differences were observed in the potency of any of the compounds tested in inhibiting CNT3 reference and its three nonsynonymous polymorphisms (Table 3) . Although studies in heterologous expression systems, such as X. laevis oocytes, can accurately assess substrate and inhibitor potencies (K i ) and may reflect in vivo potencies in various tissues, the same is not the case for maximum transport rates. The maximum transport rate (V max ) of a substrate is a function of both the expression level of the transporter on the plasma membrane and its turnover rate constant. In oocytes, V max is controlled by the quantity of mRNA injected, its stability in the cells, and the rate of translation, trafficking, and degradation of the transporter. Obviously, these factors would vary in different tissues in the body.
In summary, we have determined that CNT3 has a high degree of genetic and functional constraints. This transporter is under strong negative selection, which is acting to preserve its amino-acid sequence. It is possible that, due to its primary role in maintaining homeostasis of endogenous compounds, CNT3 is critical for human fitness. The three common amino-acid variants of CNT3 (p. Ser5Asn, p. Tyr113Cys, and p. Ile328Val) interact with the antileukemic analogs, cladribine and fludarabine, similarly to CNT3 reference. It remains to be determined whether genetic variation in other regions of SLC28A3 can explain the observed variation in the expression levels of this transporter and in the clinical response to the adenosine nucleoside analogs in leukemia patients.
MATERIALS AND METHODS
Identification of SLC28A3 Variants
Genomic DNA samples were collected from unrelated healthy individuals in the San Francisco Bay Area as part of the Studies of Pharmacogenetics in Ethnically Diverse Populations (SOPHIE) project. SLC28A3 variants were identified by direct sequencing of genomic DNA as previously described 24 from an ethnically diverse population of 270 individuals: 80 African-Americans, 80 European-Americans, 60 Asian-Americans (50 Chinese-Americans and 10 JapaneseAmericans), and 50 Mexican-Americans. The reference cDNA sequence of SLC28A3 was obtained from GenBank (http:// www.ncbi.nlm.nih.gov, accession number AF305210.1). Primers were designed manually to span the exons and 50-200 bp of flanking intronic sequence. The primer sequences can be found at http://www.pharmgkb.org. The genomic structure of SLC28A3 was based on a recent analysis by Toan et al. 25 Variant positions are relative to the ATG start site and are based on the reference cDNA sequence of SLC28A3.
Genetic Analysis of SLC28A3
The neutral parameter (y), nucleotide diversity (p), and Tajima's D statistic were calculated as described by Tajima. 26 Each parameter was determined for various sites within the coding region of SLC28A3 (eg synonymous and nonsynonymous sites, and sites within transmembrane domains and loops) for the entire population and for each ethnic group. Synonymous and nonsynonymous sites were defined as described by Hartl and Clark. 27 Haplotypes were inferred from variant sites using the Bayesian statistical method of PHASE. 9 Before PHASE analysis, all singleton samples were removed. Only haplotypes that were found in at least seven of 10 PHASE runs were reported.
Construction of SCL28A3 Variants
Human CNT3 cDNA (GenBank accession number AF305210.1) was subcloned into the mammalian expression vector pOX to obtain CNT3-reference. CNT3 reference corresponds to the coding region in the SCL28A3 *1A1 haplotype (reference haplotype), which had the highest frequency in all ethnic groups. The QuikChange sitedirected mutagenesis kit (Stratagene, La Jolla, CA, USA) was used to construct each amino-acid variant of CNT3 following the manufacturer protocol. In all cases, CNT3 reference in pOX was used as the template, except for CNT3: p. Gly367Arg-reversed, which used CNT3: p. Gly367Arg as the template. The variants were confirmed by DNA sequencing and were fully sequenced to verify that they only had the desired change.
Functional Studies of SLC28A3 Variants in Oocytes
Healthy stage V and VI X. laevis oocytes were injected with 10-30 ng of capped cRNA transcribed in vitro using T3 RNA polymerase (mCAP RNA capping kit; Stratagene) from NotIlinearized pOX plasmids containing reference or variant CNT3 cDNA. Before injection, an aliquot of the cRNA was run on an agarose gel to verify that none of the RNA was degraded. RNA concentrations were measured using a spectrophotometer. The injected oocytes were stored in modified Barth's medium at 181C for 72 h prior to transport experiments. Groups of seven to nine oocytes were incubated in the presence of Na þ in buffer containing 0.1 mM 3 H-inosine (30 Ci/mmol; Moravek), 3 H-thymidine (61 Ci/ mmol; Moravek), 3 H-adenosine (24 Ci/mmol; Moravek), 3 H-cladribine (17 Ci/mmol; Moravek), or 3 H-fludarabine (6 Ci/mmol; Moravek) and 1 mM of the respective unlabeled substrate at room temperature for 60 min. Uptake was stopped by washing the oocytes five times with ice-cold Na þ free buffer in which Na þ was replaced by choline. Oocytes were then lysed individually with 100 ml of 10% SDS and the radioactivity associated with each oocyte was determined. Variant data were normalized to the uptake of CNT3-reference for each experiment. Data are presented as mean of normalized value7SE. Uninjected oocytes, oocytes injected with CNT3-reference, and oocytes incubated with Na þ -free buffer containing 3 H-inosine served as controls within each batch of oocytes. For inhibition kinetic studies, oocytes were incubated with 0.1 mM 3 H-inosine (30 Ci/ mmol; Moravek) and varying concentrations of unlabeled adenosine (0-500 mM), cladribine (0-1500 mM), or fludarabine (0-6800 mM) at room temperature for 5-20 min. All experiments were repeated two to three times using different batches of oocytes. Uninjected oocytes served as controls within each batch of oocytes. Data are reported as mean7SE. To determine apparent K i values, data were fit using nonlinear regression analysis as described previously. 28 Statistical analysis for the functional studies was carried out by comparing the raw uptake data or K i values of each variant to those of CNT3 reference using the unpaired Student's t-test (Primer of Biostatistics software, Version 3, written by Stanton A Glantz, McGraw-Hill Companies, 1991). In each case, Bonferroni correction was applied to adjust for multiple testing. study was supported by the General Clinical Research Center at San Francisco General Hospital, funded by the National Center for Research Resources, National Institutes of Health (grant MO1-RR00083-42). We thank Jennifer Gray and Ryan Owen for their thoughtful advice and technical assistance.
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